Company news

Immunic, Inc. news in 2020

Immunic, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Immunic, Inc. to Participate in Investor Conferences in December

November 23, 2020

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

November 16, 2020

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

November 1, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

September 27, 2020

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

September 10, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

August 19, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 9, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

August 1, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

July 29, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

July 26, 2020

Immunic, Inc. to Join Russell 3000® Index

June 21, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

June 14, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

June 8, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

May 18, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

May 12, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity

May 7, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing

April 22, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

April 20, 2020

Immunic, Inc. Announces Changes to Executive Team

April 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

March 15, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

January 7, 2020

Decks in 2020